October 2023 Update: In a study published in the Journal of the American Medical Association (JAMA) on October 5, 2023, researchers identified that Ozempic users face a threefold increased risk of stomach paralysis when compared to those using Contrave (bupropion-naltrexone)
Excessive loss of lean mass is an important issue, especially in an older population, and must be in the forefront of approaches to develop better drugs for chronic weight management and chronic disease management
Similarly, Amgens AMG133 (Aridebart Cafraglutide) combines a GIPR monoclonal antibody antagonist and two GLP-1 agonist peptides
Novo Nordisk is trying to hold on to its franchise as this shift unfolds
When analyzing our scRNA-seq data, we observed that three additional granin family members: Scg2 (Secretogranin II), Chga (Chromogranin A) and Scg3 (Secretogranin III), were upregulated in cells following glucagon receptor disruption (Supplementary Fig